Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Usmani on Situations that Indicate the Need for Immediate Treatment in R/R Multiple Myeloma

February 14th 2020

Saad Z. Usmani, MD, FACP, discusses the need for immediate treatment intervention in patients with relapsed/refractory multiple myeloma.

Navigating Triplet Therapies in Relapsed/Refractory Multiple Myeloma

February 14th 2020

Saad Z. Usmani, MD, expands on some of the key principles to inform the treatment of patients with relapsed/refractory multiple myeloma.

Phasing Out Doublet Regimens in Relapsed/Refractory Multiple Myeloma

February 12th 2020

Barry Paul, MD, discusses some of the newer data to emerge regarding relapsed/refractory multiple myeloma.

Dr. Paul on the Role of Carfilzomib in Relapsed/Refractory Multiple Myeloma

February 12th 2020

Barry A. Paul, MD, discusses the role of carfilzomib in the treatment of patients with relapsed/refractory multiple myeloma.

FDA Approval Sought for Daratumumab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Myeloma

February 11th 2020

A supplemental Biologics License Application has been submitted to the FDA for daratumumab for use in combination with carfilzomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Atrash on Investigational Combinations With Venetoclax in Relapsed/Refractory Multiple Myeloma

February 11th 2020

Shebli Atrash, MD, discusses investigational combinations with venetoclax (Venclexta) in relapsed/refractory multiple myeloma.

Novel Agents Move Through Relapsed/Refractory Myeloma Pipeline

February 10th 2020

Shebli Atrash, MD, discusses some of the latest intriguing research in relapsed/refractory multiple myeloma.

CAR-T Paving New Path in Relapsed/Refractory Myeloma

February 7th 2020

Peter Voorhees, MD, provides an overview of the many developments made with CAR T-cell therapy in multiple myeloma, as well as the exciting research being done with bispecific antibodies

Dr. Shah on Potential for Daratumumab Maintenance in Multiple Myeloma

February 7th 2020

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the potential for daratumumab (Darzalex) maintenance therapy in multiple myeloma.

JNJ-4528 Boasts High Response Rate in Relapsed/Refractory Myeloma

February 6th 2020

Deepu Madduri, MD, discusses the results of the CARTITUDE-1 trial and the next phase of development with JNJ-4528.

Dr. Usmani on Treatment Considerations in Relapsed/Refractory Multiple Myeloma

February 6th 2020

Saad Z. Usmani, MD, FACP, discusses treatment considerations in relapsed/refractory multiple myeloma.

Dr. Voorhees on the Role of CAR T-Cell Therapy in Multiple Myeloma

February 5th 2020

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

Dr. Atrash on the BELLINI Trial Results in Relapsed/Refractory Multiple Myeloma

February 4th 2020

Shebli Atrash, MD, discusses the results of the BELLINI trial examining patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin Myeloma Application Fast-Tracked in EU

February 3rd 2020

The European Medicines Agency has validated a Marketing Authorization Application for belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor, and a CD38-directed monoclonal antibody.

Experts Share What They're Going to Work on Improving in Practice This Year

February 1st 2020

OncLive interviewed experts at the State of the Science Summits™ in January 2020 on what they are going to work on improving in clinical practice this year.

Dr. Biran on Post-ASCT Consolidation in Multiple Myeloma

February 1st 2020

Noa Biran, MD, physician, discusses elotuzumab (Empliciti) as post-autologous stem cell transplant consolidation in patients with high-risk myeloma.

Dr. Ghobrial on Triplet Regimen in Smoldering Myeloma

January 31st 2020

Irene Ghobrial, MD, discusses the combination of ixazomib (Ninlaro), lenalidomide (Revlimid), and dexamethasone in smoldering multiple myeloma.

Dr. Paner on HORIZON Trial in Multiple Myeloma

January 30th 2020

Agne Paner, MD, director, discusses the phase II HORIZON trial in relapsed/refractory multiple myeloma.

Dr. Hari on CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

January 30th 2020

Parameswaran Hari, MD, MRCP, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

CAR-T, Novel Combos Continue to Show Benefit in Multiple Myeloma

January 29th 2020

Larry Anderson, MD, PhD, discusses emerging therapies for patients with multiple myeloma that were highlighted at the 2019 ASH Annual Meeting.